/stocks — the workspaceLOADING
All EIKNSEC filings, by type → · Earnings date & implied move · Search inside filings
Eikon Therapeutics, Inc. (EIKN) is a biological products, (no diagnostic substances) company. 1 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind EIKN’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
A plain-English read on EIKN plus an auto-SWOT — built from EIKN's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate EIKN using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has EIKN been issuing shares? Offering history →
No lawmaker has disclosed a trade in EIKN under the STOCK Act.
No tracked institution reported a position in EIKN in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IWM iShares Russell 2000 ETF | <0.01% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
| Column Group IV GP, LP10% owner | BUY | $1.0M | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Millbrae, California, United States · the company’s charter and its head office are in different states.
Source: the cover page of Eikon Therapeutics, Inc.’s 10-Q filed 2026-08-13, on EDGAR. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Projected from EIKN's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentEIKN files or announces.
EIKN has rallied after 3 of its last 3 earnings reports.
Each figure is one earnings reaction — how much EIKN moved from the closing price the day before a report to the close the day after. Based on its last 3 reports.
Large earnings reactions have been common.
EIKN has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+15.8% and 6.0%).
A more typical earnings reaction has been approximately ±7.8%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-13 | +6.0% |
| 2026-05-11 | +15.8% |
| 2026-03-30 | +7.8% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.